Daniel G. Welch
Daniel G. Welch has served as a Director since June 2007. Since January 2015, Mr. Welch has been Executive Partner of Sofinnova Ventures. Prior to joining Sofinnova, he was Chief Executive Officer and President of InterMune. since 2003, and in May 2007 he assumed the additional role of Chairman of the Board of InterMune until its acquisition by Roche in October 2014. Previously, he was Chairman and Chief Executive Officer of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Prior to that, he was President of Biopharmaceuticals at Elan Corporation. During his tenure at Elan he was responsible for its U.S. commercial operations, international subsidiaries, R&D and diagnostics businesses. From 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo, now Sanofi-Aventis, including Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business.
Mr. Welch holds a B.A. from the University of Miami and an M.B.A. from the University of North Carolina. Mr. Welch also serves as a director of Intercept Pharmaceuticals, Ultragenyx Pharmaceuticals and AveXis.